Jewish News 24 · Nov 20, 2026
Jewish News 24 — photo status
💊 NEW PANCREATIC CANCER DATA: DARAXONRASIB PLUS CHEMO SHOWS PROMISE: In an early-phase trial of 61 patients with previously untreated metastatic pancreatic cancer, the pill daraxonrasib combined with chemotherapy controlled disease in about 90% of patients, shrank tumors in about 61% and produced complete responses in 8%. Median progression-free survival was 12.8 months, the company said at a cancer conference. Separately, in a larger phase 3 trial of previously treated patients, those on daraxonrasib survived a median of 13.2 months versus 6.7 months on chemotherapy. The FDA approved the once-daily pill in August for previously treated metastatic pancreatic cancer; the combination is not yet approved. Researchers call the findings encouraging, but the treatment isn't a cure.
More from Jewish News 24
- Jewish News 24Nov 21, 2026 · 🇮🇱 IDF: 70% OF WOUNDED SOLDIERS RETURNED TO SERVICE: The I

- Jewish News 24Nov 21, 2026 · A performance artist painted a stunningly realistic picture

- Jewish News 24Nov 21, 2026 · UBER EATS LAUNCHES DRONE DELIVERY: Uber Eats has partnered w

- Jewish News 24Nov 21, 2026 · U.S. CENTRAL COMMAND - FACT CHECK

- Jewish News 24Nov 21, 2026 · Masked immigration officers detained two people on a crowded

- Jewish News 24Nov 21, 2026 · WATCH: RUSSIAN MISSILE STRIKE CAUGHT ON DASHCAM: Dashcam foo
